NEW DPCO LIST EFFECTIVE FROM 01.04.2019 - NPPA INDIA - PART-1
(Published in Part II, Section 3, Sub-section (ii) of the Gazette of
India, Extraordinary)
New Delhi, 29th
March, 2019
ORDER
S. O. In exercise of the powers conferred by
paragraphs 5, 11 and 15 of the Drugs (Prices Control) Order, 2013, read with
S.O. 1394(E) dated the 30th May, 2013 and S. O. 701(E) dated 10th
March, 2016 issued by the Government of India in the Ministry of Chemicals and
Fertilizers, the National Pharmaceutical Pricing Authority (hereinafter
referred as NPPA), hereby fixes, the price as specified in column (6) of the
table herein below as the retail price, exclusive of goods and services tax, if any, in relation to the
formulation specified in the corresponding entry in column (2) of the said
Table with the strength, unit and name of manufacturer & marketing company,
as specified in the corresponding entries in columns (3), (4) and (5) thereof;
Table
Sl. No.
|
Name of the Formulation / Brand Name
|
Strength
|
Unit
|
Manufacturer & Marketing Company
|
Retail Price (Rs.)
|
(1)
|
(2)
|
(3)
|
(4)
|
(5)
|
(6)
|
1.
|
Sodium Fusidate +
Halobetasole Cream |
Cream contains:
Sodium Fusidate IP eq. to Fusidic Acid 2% w/w, Halobetasole Propionate USP 0.05% w/w |
1 gm
|
M/s Apex Laboratories
Private Limited
|
12.92
|
2.
|
Metformin + Glimepiride
Tablet (Azulix 0.5 MF)
|
Each Uncoated Bilayered
Tablet contains:
Glimepiride IP 0.5mg, Metformin Hydrochloride IP 500mg (As Prolonged Release Form) |
1 Tablet
|
M/s Pure and Cure
Healthcare Pvt. Ltd. / M/s Torrent Pharmaceuticals Limited
|
3.58
|
3.
|
Escitalopram + Clonazepam
Tablet (Newcita Mini)
|
Each film coated tablet
contains:
Escitalopram Oxalate IP eq. to Escitalopram 5mg, Clonazepam IP 0.5mg |
1 Tablet
|
M/s Ravian Life Science
Pvt. Ltd. / M/s Alkem Laboratories Ltd.
|
6.10
|
4.
|
Ceftriaxone +
Sulbactum Injection (Taxone SB 1000mg ) |
Each vial contains:
Ceftriaxone Sodium IP eq. to Ceftriaxone 1gm Sulbactum Sodium USP eq. to Sulbactum 500mg |
1 vial
|
M/s Mapra Laboratories
Pvt. Ltd.
|
110.95
|
5.
|
Ceftriaxone +
Sulbactum Injection (Taxone SB 250mg ) |
Each vial contains:
Ceftriaxone Sodium IP eq. to Ceftriaxone 250gm Sulbactum Sodium USP eq. to Sulbactum 125mg |
1 vial
|
M/s Mapra Laboratories
Pvt. Ltd.
|
43.21
|
6.
|
Ceftriaxone +
Sulbactum Injection (Taxone SB 500mg ) |
Each vial contains:
Ceftriaxone Sodium IP eq. to Ceftriaxone 500gm Sulbactum Sodium USP eq. to Sulbactum 250mg |
1 vial
|
M/s Mapra Laboratories
Pvt. Ltd.
|
71.60
|
7.
|
Atorvastatin + Fenofibrate Tablet
|
Each film coated Tablet
contains:
Atorvastatin 10mg, Fenofibrate 160mg |
1 Tablet
|
M/s Rivpra Formulations
Pvt. Ltd. / M/s Cadila Pharmaceuticals Limited
|
11.52
|
8.
|
Hyaluronic Acid +
Lidocain Hydrochloride Injection
|
Each ml contains:
Hyaluronic Acid BP 24.0mg Lidocain Hydrochloride IP 3.00mg |
Per Pack having 2 prefilled syringe of 1 ML Each
|
M/s Virchow Biotech
Limited. / M/s Zydus Healthcare Limited
|
26987.40
|
9.
|
Emtricitabine + Tenofovir
Alafenamide tablet (Tafmune – EM)
|
Each film coated tablet contains:
Emtricitabine IP 200 mg
Tenofovir Alafenamide
Hemifumarate eq. to Tenofovir Alafenamide 25 mg
|
1 Tablet
|
M/s Hetero Labs Ltd. /
M/s Cipla Ltd.
|
55.33
|
10.
|
Tenofovir Alafenamide + Emtricitabine
Tablet (TAFICITA)
|
Each film coated
contains:
Tenofovir Alafenamide fumarate eq. to Tenofovir Alafenamide 25 mg Emtricitabine 200mg |
1 Tablet
|
M/s Mylan Laboratories
Ltd. / M/s Mylan Pharmaceuticals Pvt.
Ltd.
|
55.33
|
11.
|
Tenofovir
Alafenamide Tablet
|
Each film coated tablet
contains:
Tenofovir Alafenamide fumarate
eq. to Tenofovir Alafenamide 25 mg
|
1 Tablet
|
M/s Mylan Laboratories Ltd./ M/s Mylan Pharmaceuticals Pvt. Ltd.
|
44.29
|
12.
|
Tenofovir
Alafenamide Tablet
|
Each film coated tablet
contains:
Tenofovir Alafenamide Hemifumarate
eq. to Tenofovir Alafenamide 25 mg
|
1 Tablet
|
M/s Hetero Labs Ltd./ M/s Cipla Ltd.
|
44.29
|
13.
|
Tenofovir
Alafenamide Tablet
|
Each film coated tablet
contains:
Tenofovir Alafenamide Hemifumarate
eq. to Tenofovir Alafenamide 25 mg
|
1 Tablet
|
M/s Hetero Labs Ltd./ M/s
Cadila Healthcare Ltd.
|
44.29
|
14.
|
Tenofovir
Alafenamide Tablet
|
Each film coated tablet
contains:
Tenofovir Alafenamide Hemifumarate
eq. to Tenofovir Alafenamide 25 mg
|
1 Tablet
|
M/s Hetero Labs Ltd./ M/s
Emcure Pharmaceuticals Ltd.
|
44.29
|
15.
|
Tenofovir
Alafenamide Tablet
|
Each film coated tablet
contains:
Tenofovir Alafenamide
fumarate eq. to Tenofovir Alafenamide 25 mg
|
1 Tablet
|
M/ Natco Pharma Ltd. /
M/s Sun Pharma Laboratories Ltd.
|
44.29
|
16.
|
Tenofovir
Alafenamide Tablet
|
Each film coated tablet
contains:
Tenofovir Alafenamide fumarate
eq. to Tenofovir Alafenamide 25 mg
|
1 Tablet
|
M/ Natco Pharma Ltd. / M/s
Abbott India Ltd.
|
44.29
|
17.
|
Tenofovir
Alafenamide Tablet
|
Each film coated tablet
contains:
Tenofovir Alafenamide
fumarate eq. to Tenofovir Alafenamide 25 mg
|
1 Tablet
|
M/ Natco Pharma Ltd.
|
44.29
|
18.
|
Tenofovir
Alafenamide Tablet
|
Each film coated tablet
contains:
Tenofovir Alafenamide
fumarate eq. to Tenofovir Alafenamide 25 mg
|
1 Tablet
|
M/ Natco Pharma Ltd. / M/s
Cadila Healthcare Ltd.
|
44.29
|
19.
|
Tenofovir
Alafenamide Tablet
|
Each film coated tablet
contains:
Tenofovir Alafenamide
fumarate eq. to Tenofovir Alafenamide 25 mg
|
1 Tablet
|
M/ Natco Pharma Ltd. /
M/s Dr. Reddy’s Laboratories Ltd.
|
44.29
|
20.
|
Tenofovir
Alafenamide Tablet
|
Each film coated tablet
contains:
Tenofovir Alafenamide
fumarate eq. to Tenofovir Alafenamide 25 mg
|
1 Tablet
|
M/ Natco Pharma Ltd. /
M/s Aprazer Healthcare Pvt. Ltd.
|
44.29
|
21.
|
Emtricitabine
+ Tenofovir Alafenamide Tablet
|
Each
film coated tablet contains:
Emtricitabine IP 200mg, Tenofovir Alafenamide Hemifumarate eq. to Tenofovir Alafenamide 10mg |
1 Tablet
|
M/s
Hetero Labs Limited / M/s Cipla Limited
|
31.17
|
Note:
(a) The
manufacturer of above mentioned formulations i.e. “new drug” under paragraph
2(u) of the DPCO, 2013 shall fix the retail price as specified in column (6) of
the table hereinabove.
(b) The manufacturer
may add goods and services tax only
if they have paid actually or it is payable to the Government on the retail
price mentioned in column (6) of the above said table.
(c) The
retail price for a pack of the aforesaid formulation shall be arrived at by the
concerned manufacturer in accordance with the retail price specified in column
(6) of the above table as per provisions contained in paragraph 11 of the DPCO,
2013. The manufacturer shall issue a price list in Form–V from date of
Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers.
(d) As per para 24(4) of DPCO 2013, every retailer and dealer shall display
price list and the supplementary price list, if any, as furnished by the
manufacturer, on a conspicuous part of the premises where he carries on
business in a manner so as to be easily accessible to any person wishing to
consult the same.
(e) The
above mentioned retail price is applicable only to the individual manufacturer
/ marketer as mentioned above i.e. who have applied for the same by submitting
Form-I for price fixation / revision as stipulated under DPCO, 2013 and subject
to fulfilment of all the applicable statutory requirements as laid down by the
Govt. under relevant statutes/ rules, including manufacturing license
permission from the Competent Authority i.e. the Central/State Licensing
Authority, as may be applicable, by the concerned manufacturer/marketing
companies.
(f) In
case the retail price of any of the aforesaid formulations is not complied
with, as per instant price notification and notes specified hereinabove, then
the concerned manufacturer/marketing company shall be liable to deposit the
overcharged amount along with the interest thereon under the provisions of the
DPCO, 2013 read with the Essential Commodities Act, 1955.
(g) Consequent
to the issue of ceiling price of such formulation as specified in column (2) of
the above table in this notification, the price order(s) fixing ceiling or
retail price, if any, issued prior to the above said date of notification,
stand(s) superseded.
(Prasenjit Das)
Assistant Director
ref. by: NPPA - INDIA
Note: This is just information, Its by Government of India. this is for only information for pharmaceutical company, Medicine Retailers, Pharmacist and Other medical fraternity.
DISCLAIMER:
This is only information , if any change by government... we are not responsible for that..... For complete details please visit NPPA - Government of India Website....
added by: Green Cross Remedies
Comments
Post a Comment